# Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

> **NCT07703436** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Nuvation Bio Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Grade 2 IDH1-mutant Glioma
- Grade 3 IDH1-mutant Glioma
- Glioma
- IDH1-mutant Glioma
- Oligodendroglioma
- Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted
- Astrocytoma IDH Mutant Grade 3
- Astrocytoma IDH Mutant Grade 2

## Interventions

- **DRUG:** Safusidenib

## Key facts

- **NCT ID:** NCT07703436
- **Lead sponsor:** Nuvation Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-03
- **Primary completion:** 2030-09
- **Final completion:** 2032-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07703436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07703436, "Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07703436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*